Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497625 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2UCHL1CHRM2CHRM1 | |
| Ammonia Solution, Strong SCHEMBL28112854 | 0.98 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2UCHL1CHRM2CHRM1 | |
| SCHEMBL721105 | 0.88 | PTPN1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL19566140 | 0.88 | NPC1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL717566 | 0.88 | PTPN1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL85511 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL204965 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL204966 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL22543468 | 0.85 | PTPN1 (0.46) | HSD17B10UCHL1NPC1PTPN1 | |
| SCHEMBL10058225 | 0.85 | PTPN1 (0.46) | HSD17B10UCHL1NPC1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| CN-105793242-B | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | 伊莱利利公司 | 2018-02-16 | — | — | CN | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3083562-B1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3083562-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | Eli Lilly & Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| CN-105793242-A | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators | 伊莱利利公司 | 2016-07-20 | — | — | CN | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| WO-2015094902-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| US-20120053350-A1 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | MERCK SHARP & DOHME CORP. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | HSD17B10 4434/4885SMN1; SMN2 411/4885UCHL1 3879/4885 |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | HSD17B10 3686/4885SMN1; SMN2 4442/4885UCHL1 4843/4885 |
| US-20120053350-A1 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | SULT1A1, SULT1E1, PGD | HSD17B10 338/4885SMN1; SMN2 3145/4885UCHL1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.